Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Melinda L. Telli, Sara M. Tolaney et al.|JAMA Oncology|2019Cited by 446
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.Shaveta Vinayak, Melinda L. Telli, Sara M. Tolaney et al.|Journal of Clinical Oncology|2018Cited by 77
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastasesAmanda E.D. Van Swearingen, Carey K. Anders, Marni B. Siegel et al.|Breast Cancer Research and Treatment|2018Cited by 48
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).Carey K. Anders, Lisa A. Carey, Allison M. Deal et al.|Journal of Clinical Oncology|2017Cited by 4
Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)Veronica Mariotti, Hatem Soliman, Roohi Ismail‐Khan et al.|Cancer Research|2020Cited by 2